FOLH1 and pachyonychia congenita: 18F-DCFPyL is a further PSMA based PET ligand and in a study including more than 400 patients with PC of all Gleason scores achieved an excellent performance in staging with a detection rate of nearly 90% for PSA ≥ 0.5ng/ml and about 50% for lower PSA values (21).